MEMPHIS, Tennessee : Cognate BioServices, a top contract development and manufacturing organization (CDMO) experts in cell and cell-mediated gene therapy products revealed that it has completed the acquisition of Cobra Biologics, a key CDMO specialized in furnishing development and manufacturing services for plasmid DNA and viral vector.
Prevailing Cognate shareholder, EW Healthcare Partners and its co-investors guided the investment in Cognate and the financing for the acquisition of Cobra, with participation from Medivate.
With the addition of Cobra's expert skills in plasmid DNA, viral vectors, protein and microbiota, from development to fill-finish, Cognate is well-positioned as a worldwide industry-leading services contributor to deliver drug development and manufacturing solutions to the cell and gene immunotherapy and regenerative medicine industry all over the globe.
Cobra Biologics has cGMP units in the UK and Sweden. Cognate runs an 80,000+ square foot manufacturing unit situated in Memphis, TN, and a devoted advancement wing in Baltimore.
"We are all thrilled to close this transaction and start delivering on our combined value proposition," observed J. Kelly Ganjei, CEO of Cognate. "The combined Cognate-Cobra expertise, infrastructure, and geographical footprint immediately position both businesses to address current and future market needs more quickly, effectively, and comprehensively, with our focus of owning and optimizing the complex aspects of the supply chain. In support of this acquisition we have been working to expand our commercial capacity and capabilities to effectively provide a unique, scalable option for drug development and manufacturing to our clients and their patients."
This transaction further backs Cognate's objective to meet the requirements of the ultimate client of its services — the patients with unmet medical requirements while maintaining concentration on furnishing swift access to advanced manufacturing capabilities integrated into a scalable manufacturing environment.
About Cognate BioServices, Inc.
Cognate is a dynamic, results-propelled, organization concentrated on furnishing the widest array of commercialization services to regenerative medicine, cellular immunotherapy and advance cell therapy companies. Cognate furnishes an exclusive combination of custom services to companies across all points of clinical and business advancement specializing in mid to late stage clinical trials and supporting clients via product scale-up into commercial manufacturing. Cognate applies the learning and specialization of its business, scientific and technical squads to successfully develop autologous and allogeneic products across multiple cell-based expertise platforms from commencement to conclusion.
About Cobra Biologics:
Cobra Biologics is a top global advanced therapy CDMO with GMP authenticated units in both Sweden and the UK each with a vast track record in serving the worldwide customer base. It presents a wide array of integrated and stand-alone services for both the clinical and commercial market. As a loyal furnisher and a leading collaborator in the drug advancement and commercialization process, the company boasts of its manufacturing brilliance and thorough array of services to the pharmaceutical and biotech industries.
About EW Healthcare Partners:
With nearly $4 billion raised since commencement, EW Healthcare Partners is one of the leading and oldest private healthcare investment firms and attempts to make expansion equity investments in rapidly expanding commercial-stage healthcare companies in the pharmaceutical, medical device, diagnostics, and technology-enabled services segments in the United States and in Europe. Since its establishment in 1985, EW Healthcare Partners has maintained its singular dedication to the healthcare industry and has been a long term investor in over 150 healthcare companies, varying across segments, stages and geographies. The team consists of over 20 veteran investment experts with offices in Palo Alto, Houston, New York, and London.
About Medivate Partners:
Medivate is a private equity and venture capital firm that concentrates investment in biotech/healthcare industry in Asia and North America. The firm is well placed to secure growing healthcare investment scopes between Asia and North America, and looks to arbitrage the exclusive cross border investment benefits. While concluding its third fund, Medivate Partners swiftly created a fame for furnishing inner circle access to leading caliber syndicates and successful life science deals in Asia and North America.
By ANJISHNU BISWAS
No comments:
Post a Comment